UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.16 Million Holdings in Novavax, Inc. (NASDAQ:NVAX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Novavax, Inc. (NASDAQ:NVAX - Free Report) by 19.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 268,684 shares of the biopharmaceutical company's stock after acquiring an additional 44,359 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.17% of Novavax worth $2,160,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in NVAX. Spire Wealth Management bought a new position in Novavax in the fourth quarter valued at about $29,000. New Age Alpha Advisors LLC bought a new position in Novavax in the fourth quarter valued at about $35,000. KBC Group NV grew its position in shares of Novavax by 97.0% during the 4th quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock worth $64,000 after buying an additional 3,917 shares during the period. TigerOak Management L.L.C. acquired a new stake in shares of Novavax during the 4th quarter worth approximately $86,000. Finally, AlphaQuest LLC grew its position in shares of Novavax by 290.1% during the 4th quarter. AlphaQuest LLC now owns 10,677 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 7,940 shares during the period. Institutional investors and hedge funds own 53.04% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on NVAX. JPMorgan Chase & Co. lowered their price target on shares of Novavax from $9.00 to $7.00 and set an "underweight" rating for the company in a research report on Friday, May 9th. B. Riley reiterated a "buy" rating on shares of Novavax in a research report on Monday, May 19th. TD Cowen upgraded shares of Novavax to a "hold" rating in a research report on Thursday, February 27th. Finally, BTIG Research began coverage on shares of Novavax in a research report on Friday, February 28th. They set a "buy" rating and a $19.00 price target for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, Novavax currently has a consensus rating of "Hold" and an average target price of $19.00.

Novavax Stock Down 2.8%

NASDAQ NVAX traded down $0.21 during trading on Tuesday, reaching $7.20. 5,577,079 shares of the stock traded hands, compared to its average volume of 6,646,245. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of -3.19, a price-to-earnings-growth ratio of 2.85 and a beta of 2.80. The stock's 50-day moving average price is $6.67 and its 200 day moving average price is $7.75. Novavax, Inc. has a fifty-two week low of $5.01 and a fifty-two week high of $17.81.

Novavax (NASDAQ:NVAX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $2.93 EPS for the quarter, topping analysts' consensus estimates of $0.71 by $2.22. The business had revenue of $666.66 million for the quarter, compared to analyst estimates of $204.08 million. The company's revenue for the quarter was up 610.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.05) EPS. Analysts anticipate that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.